People · Operator
Named in public records as an officer, director or promoter · active 2015–2021 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ensoma, Inc. | — | Biotechnology | Series D+ | $169.6M | $2.3B | 2021 |
| Homology Medicines, Inc. | — | Pharmaceuticals | Series C | $127.1M | $2.9B | 2015 |
Albert Seymour at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Albert Seymour on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kush Parmar | 2 | 10 |
| Steven Gillis | 1 | 23 |
| Cameron Wheeler | 1 | 9 |
| Brad Smith | 1 | 6 |
| STEPHEN KNIGHT | 1 | 6 |
| Mahendra Shah | 1 | 5 |
| Paul Stone | 1 | 5 |
| KUSH M. PARMAR | 1 | 3 |
| Nihal Sinha | 1 | 2 |
| Emile Nuwaysir | 1 | 2 |
| Richard Gregory | 1 | 2 |
| Arthur Tzianabos | 1 | 2 |
| Kouki M Harasaki | 1 | 1 |
| Mark M Chin | 1 | 1 |
| Albert M Seymour | 1 | 1 |
| Siyamak Rasty | 1 | 1 |
| Paula Soteropoulos | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.